Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases
Key facts
- Who runs it
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 21 people enrolled
- Started
- 27 Jun 2023
- Ended
- 25 Jul 2025
- Type of study
- Interventional
- Treatments tested
- biological samples (blood test and lumbar puncture)
- Record updated
- 24 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patient aged 18 or over
- Patient with cerebral metastases from a solid cancer, at least one of which is accessible to surgical excision (contrast enhancement of at least 1 cm)
- Patient able to understand the information related to the study and to read the information leaflet
- Patient having signed a written informed consent to participate in the study
Who cannot take part
- Patient with a medical contraindication to surgery and anesthesia
- Patient whose anatomical location of the cerebral metastasis contraindicates wide resection
- Patient with a contraindication to performing a lumbar puncture
- Pregnant, parturient or breastfeeding women
- Patient participating in another clinical trial, or in a period of exclusion from another clinical trial
- Patient under guardianship or curatorship, or under a regime of deprivation of liberty
- Patient not benefiting from a social security scheme
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to determine in brain metastases and according to feasibility in liquid biopsies:
Read full original descriptionShow less
* Molecular alterations including in particular mutations, amplifications, Copy number gene variants and fusion transcripts identified by high-throughput sequencing; * The rate of variation either in gain or in loss of expression of the different messenger Ribonucleic Acids by analysis of the transcriptome; * Epigenetic alterations by methylation of deoxyribonucleic acid clusters by methylome chips.
The group in the trial
- brain metastases from solid cancerOther group
Excision of the cerebral metastasis
Treatment: biological samples (blood test and lumbar puncture)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 November 2025